Histogen (HSTO) Competitors $0.0003 0.00 (0.00%) As of 08/13/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock HSTO vs. NMTR, AMPE, PXMD, CALA, EFTR, ONCSQ, ATNFW, LBPSW, AEHAW, and AIMDWShould you be buying Histogen stock or one of its competitors? The main competitors of Histogen include 9 Meters Biopharma (NMTR), Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), and Ainos (AIMDW). These companies are all part of the "pharmaceutical products" industry. Histogen vs. Its Competitors 9 Meters Biopharma Ampio Pharmaceuticals PaxMedica Calithera Biosciences eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Histogen (NASDAQ:HSTO) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Which has more risk & volatility, HSTO or NMTR? Histogen has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Which has stronger valuation and earnings, HSTO or NMTR? Histogen has higher revenue and earnings than 9 Meters Biopharma. Histogen is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHistogen$19K0.07-$10.62M-$2.810.009 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Is HSTO or NMTR more profitable? Histogen's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets HistogenN/A N/A N/A 9 Meters Biopharma N/A -584.97%-159.45% Do insiders & institutionals have more ownership in HSTO or NMTR? 22.3% of 9 Meters Biopharma shares are held by institutional investors. 3.3% of Histogen shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to HSTO or NMTR? In the previous week, Histogen's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score. Company Overall Sentiment Histogen Neutral 9 Meters Biopharma Neutral SummaryHistogen beats 9 Meters Biopharma on 6 of the 9 factors compared between the two stocks. Get Histogen News Delivered to You Automatically Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HSTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart HSTO vs. The Competition Export to ExcelMetricHistogenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$852.35M$5.66B$9.82BDividend YieldN/A4.84%3.79%4.07%P/E Ratio0.001.1930.5825.12Price / Sales0.0726.45462.14114.81Price / CashN/A19.5637.4059.05Price / Book0.006.589.096.18Net Income-$10.62M-$4.98M$3.25B$264.89M7 Day PerformanceN/A3.15%7.32%4.18%1 Month PerformanceN/A2.26%5.41%1.99%1 Year PerformanceN/A14.15%30.66%24.22% Histogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020NMTR9 Meters BiopharmaN/A$0.00+∞N/AN/A$3KN/A0.0020Gap UpAMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020PXMDPaxMedicaN/A$0.00+100.0%N/AN/A$2KN/A0.002Gap UpCALACalithera Biosciences0.6061 of 5 stars$0.00-66.7%N/A-92.0%$1KN/A0.0060Gap DownEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.6%$1KN/A0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040ATNFW180 Life SciencesN/A$0.01+1.0%N/A+4,157.4%$0.00N/A0.007News CoverageGap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01+84.9%N/A-87.3%$0.00N/A0.002Gap DownAIMDWAinosN/A$0.35+220.2%N/AN/A$0.00$106.21K0.0040Gap UpHigh Trading Volume Related Companies and Tools Related Companies 9 Meters Biopharma Competitors Ampio Pharmaceuticals Competitors PaxMedica Competitors Calithera Biosciences Competitors eFFECTOR Therapeutics Competitors OncoSec Medical Competitors 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSTO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access